Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 4/20 | 0.59 |
| ▸ | CDK8 | P49336 | 2/20 | 0.59 |
| ▸ | TNIK | Q9UKE5 | 2/20 | 0.59 |
| ▸ | JAK2 | O60674 | 2/20 | 0.57 |
| ▸ | ROS1 | P08922 | 2/20 | 0.57 |
| ▸ | MARK3 | P27448 | 2/20 | 0.57 |
| ▸ | FLT3 | P36888 | 2/20 | 0.57 |
| ▸ | STK3 | Q13188 | 2/20 | 0.57 |
| ▸ | PLK4 | O00444 | 1/20 | 0.57 |
| ▸ | AURKA | O14965 | 1/20 | 0.57 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.57 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.57 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.57 |
| ▸ | PRKCG | P05129 | 1/20 | 0.57 |
| ▸ | INSR | P06213 | 1/20 | 0.57 |
| ▸ | CDK1 | P06493 | 1/20 | 0.57 |
| ▸ | FES | P07332 | 1/20 | 0.57 |
| ▸ | IGF1R | P08069 | 1/20 | 0.57 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.57 |
| ▸ | PHKG2 | P15735 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19351251 | 0.99 | AXL (0.61) | AXLCDK8TNIKJAK2ROS1 | |
| SCHEMBL19068207 | 0.88 | NTRK1 (0.53) | AXLCDK8TNIKROCK2KIT | |
| SCHEMBL19068206 | 0.88 | ROCK2 (0.61) | ROCK2DYRK1ALRRK2KITNTRK1 | |
| SCHEMBL19068203 | 0.87 | NTRK1 (0.54) | AXLCDK8TNIKKITNTRK1 | |
| SCHEMBL19351228 | 0.86 | DYRK1A (0.59) | ROCK2CDK2DYRK1ALRRK2KIT | |
| SCHEMBL17952137 | 0.81 | AXL (0.52) | AXLCDK8TNIKJAK2ROS1 | |
| SCHEMBL17951906 | 0.79 | AXL (0.53) | AXLCDK8TNIKJAK2ROS1 | |
| SCHEMBL21557922 | 0.79 | BRD4 (0.40) | ROCK2MAP4K4JAK3 | |
| SCHEMBL18860555 | 0.79 | BRD4 (0.40) | ROCK2MAP4K4JAK3 | |
| SCHEMBL18860544 | 0.77 | BRD4 (0.41) | JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190106439-A1 | HETEROCYCLIC ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | CONFLUENCE LIFE SCIENCES, INC. | 2019-04-11 | — | — | US | disclosed |
| US-20170260211-A1 | HETEROCYCLIC ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | ACLARIS THERAPEUTICS, INC. | 2017-09-14 | — | — | US | disclosed |
| US-9695200-B2 | Heterocyclic ITK inhibitors for treating inflammation and cancer | CONFLUENCE LIFE SCIENCES, INC. (US) | 2017-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190106439-A1 | HETEROCYCLIC ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | ITK, NFKBIA, TNNI3K | AXL 3309/4885CDK8 395/4885TNIK 8/4885 |
| US-20170260211-A1 | HETEROCYCLIC ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | ITK, NFKBIA, TNNI3K | AXL 3309/4885CDK8 395/4885TNIK 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.